Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Search Strategy for NMA_Diabetes - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="264328"/>
  <meta>
    <versionId value="5"/>
    <lastUpdated value="2024-07-29T12:57:50.116Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/search-strategy"/>
  </meta>
  <text>
    <status value="empty"/>
    <div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Sheyu Li"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="Search Strategy for NMA_Diabetes [Database Entry: FHIR Group Resource]. Contributors: Sheyu Li [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 264328. Revised 2024-07-26. Available at: https://fevir.net/resources/Group/264328. Computable resource at: https://fevir.net/resources/Group/264328."/>
    </valueRelatedArtifact>
  </extension>
  <url value="https://fevir.net/resources/Group/264328"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="264328"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title value="Search Strategy for NMA_Diabetes"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="An example of a search strategy for a systematic review."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <combinationMethod value="any-of"/>
  <characteristic>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ovid-medline-search"/>
        <display value="Ovid MEDLINE search string"/>
      </coding>
      <text value="Ovid MEDLINE search"/>
    </code>
    <valueExpression>
      <name value="MEDLINE Search"/>
      <language value="Ovid pseudocode"/>
      <expression
                  value="1 exp Diabetes Mellitus Type 
2/ 162040 2 Diabetes Mellitus/ 
3 ((diabetes or diabetes mellitus or diabetic*) adj1 (type 2 or type II or type ii or non-insulin dependent or noninsulin dependent or adult onset or mature onset or late onset)).tw. 
4 NIDDM.tw. 
5 Diabetic Nephropathies/ 
6 (diabetic nephropath* or diabetic kidney disease).tw. 
7 or/1-6 345031 156382 21055 
8 (nonsteroidal mineralocorticoid receptor antagonist* or nonsteroidal mineralocorticoid receptor inhibitor* or nonsteroidal mineralocorticoid antagonist* or nonsteroidal mineralocorticoid inhibitor* or nonsteroidal mineralocorticoid receptor antagonist* or non-steroidal mineralocorticoid receptor inhibitor* or non-steroidal mineralocorticoid antagonist* or non-steroidal mineralocorticoid inhibitor*).tw. 97 
9 (Finerenone* or kerendia* or BAY-94-8868 or BAY948862 or BAY-948862 or BAY94-8862 or BAY 948862).tw. 171 
10 (AZD9977 or AZD-9977 or AZD 9977).tw. 7 
11 (Apararenone* or MT-3995 or MT3995 or MT 3995).tw. 
12 (KBP5074 or KBP-5074 or KBP 5074).tw. 6 
13 (Esaxerenone* or CS3150 or CS-3150 or CS 3150).tw. 62 
14 glucose-dependent insulinotropic polypeptide/ 0 9 15 ((glucose-dependent insulinotropic polypeptide adj5 receptor inhibitors*) or (glucose-dependent insulinotropic polypeptide adj5 receptor agonist*) or (glucose-dependent insulinotropic polypeptide adj5 inhibitor*) or (glucose-dependent insulinotropic polypeptide adj5 agonist*) or (GIP adj5 receptor inhibitors*) or (GIP adj5 receptor agonist*) or (GIP adj5 inhibitors*) or (GIP adj5 agonist*)).tw. 16 (tirzepatide* or LY3298176 or LY-3298176 or LY 3298176).tw. 90 17 or/8-16 554 18 and/7,17 327 19 randomized controlled trial.pt. 20 controlled clinical trial.pt. 95029 21 pragmatic clinical trial.pt. 2145 577473 229 22 randomized.ab. 507551 23 randomised.ab. 103652 24 placebo.ab. 212881 25 clinical trials as topic/ 26 randomly.ab. 27 trial.ti. 238934 28 or/19-27 334494 1373150 200361 29 animals/ not (humans/ and animals/) 5017107 30 28 not 29 1253710 31 and/18,30 91"/>
    </valueExpression>
    <exclude value="false"/>
    <description value="Ovid MEDLINE search"/>
    <period>
      <end value="2022-10"/>
    </period>
  </characteristic>
  <characteristic>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ovid-embase-search"/>
        <display value="Ovid Embase search string"/>
      </coding>
      <text value="Embase (via Ovid) search"/>
    </code>
    <valueExpression>
      <name value="Ovid Embase search"/>
      <language value="Ovid pseudocode"/>
      <expression
                  value="1 exp Diabetes Mellitus Type 2/ 309094
2 Diabetes Mellitus/ 646929
3 ((diabetes or diabetes mellitus or diabetic*) adj1 (type 2 or type II or type ii or non-insulin dependent or
noninsulin dependent or adult onset or mature onset or late onset)).tw. 275418
4 NIDDM.tw. 8072
5 Diabetic Nephropathies/ 25921
6 (diabetic nephropath* or diabetic kidney disease).tw. 34660
7 or/1-6 964617
8 exp mineralocorticoid receptor antagonists/ 100683
9 (nonsteroidal mineralocorticoid receptor antagonist* or nonsteroidal mineralocorticoid receptor
inhibitor* or nonsteroidal mineralocorticoid antagonist* or nonsteroidal mineralocorticoid inhibitor* or nonsteroidal mineralocorticoid receptor antagonist* or non-steroidal mineralocorticoid receptor inhibitor* or
non-steroidal mineralocorticoid antagonist* or non-steroidal mineralocorticoid inhibitor*).tw. 170
10 (Finerenone* or kerendia* or BAY-94-8868 or BAY948862 or BAY-948862 or BAY94-8862 or BAY
948862).tw. 331"/>
    </valueExpression>
    <exclude value="false"/>
    <description value="Embase (via Ovid) search strategy"/>
    <period>
      <end value="2022-10"/>
    </period>
  </characteristic>
</Group>